Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.42 |
| ▸ | PPM1B | O75688 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.42 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.42 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1298063 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1298064 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961543 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2957502 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2851892 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297864 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL1297660 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL5776911 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2961541 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 | |
| SCHEMBL2518872 | 1.00 | CYP3A4 (0.43) | CYP3A4CYP1A2CYP2D6TSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4178620-B1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12528786-B2 | Plasma kallikrein inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-01-20 | — | — | US | disclosed |
| CN-112105610-B | Bicyclic compounds as inhibitors of PD1/PD-L1 interaction/activation | 朱比连特普罗德尔有限责任公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-11-30 | — | — | US | disclosed |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2023-11-02 | — | — | US | disclosed |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ENLIVEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-116157154-A | Plasma kallikrein inhibitors | 默沙东有限责任公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-4178620-A1 | PLASMA KALLIKREIN INHIBITORS | Merck Sharp & Dohme LLC (US) | 2023-05-17 | — | — | EP | disclosed |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2023-04-27 | — | — | US | disclosed |
| US-6391889-B2 | POTENT ANTIMICROBIAL ACTIVITY ON BROAD RANGE OF MICROORGANISMS, E.G., STAPHYLOCOCCUS, GRAMPOSITIVE BACTERIA AND QUINOLONE ANTIBIOTIC RESISTANCE; SIDE EFFECT REDUCTION; NONTOXIC | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-05-21 | — | — | US | disclosed |
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | DAIICHI PHARMACEUTICAL CO., LTD. | 2002-05-02 | — | — | US | disclosed |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | US | disclosed |
| EP-0571822-B1 | Diazabicycloalkene derivatives | DAIICHI SEIYAKU CO (JP) | 2001-08-16 | — | — | EP | disclosed |
| EP-0919553-A1 | cis-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-06-02 | — | — | EP | disclosed |
| US-5418232-A | Hypotensive, increases renal blood flow | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-05-23 | — | — | US | disclosed |
| EP-0571822-A1 | Diazabicycloalkene derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1993-12-01 | — | — | EP | disclosed |
| US-4859680-A | Pyrimidine derivatives as antiviral compounds | MERCK & CO., INC. (US) | 1989-08-22 | — | — | US | disclosed |
| US-4617304-A | VIRICIDE; HERPES | MERCK & CO., INC. (US) | 1986-10-14 | — | — | US | disclosed |
| EP-0159264-A2 | Antiviral compounds | MERCK & CO. INC. (US) | 1985-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020052502-A1 | Cis-substituted aminocyclopropane derivative | SLC11A2, MYD88, ARG1 | CYP3A4 472/4885CYP1A2 825/4885CYP2D6 144/4885 |
| US-20020002182-A1 | CIS-SUBSTITUTED AMINOCYCLOPROPANE DERIVATIVES | PHOSPHO1, CCR2, ECH1 | CYP3A4 1440/4885CYP1A2 1677/4885CYP2D6 1571/4885 |
| US-20230348428-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, SERPINE1, KLK5 | CYP3A4 2585/4885CYP1A2 2776/4885CYP2D6 3203/4885 |
| US-11807638-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
| US-20230382907-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
| US-12528786-B2 | Plasma kallikrein inhibitors | CFH, KLKB1, SERPINH1 | CYP3A4 3325/4885CYP1A2 3838/4885CYP2D6 2279/4885 |
| US-11767321-B2 | 5- and 6-azaindole compounds for inhibition of BCR-ABL tyrosine kinases | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
| US-20230130724-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | CYP3A4 3060/4885CYP1A2 2919/4885CYP2D6 2057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.